

Medical Contract Manufacturing

SEGMENT SPOTLIGHT



Q1 2023

Houlihan Lokey's Global Medical Technology Team



Keith Barry Managing Director Head of Medical Technology KBarry@HL.com 415.273.3708



Jon Guskind Managing Director JGuskind@HL.com 212.497.7807



Paul Tomasic Managing Director Head of European Healthcare PTomasic@HL.com +44 (0) 20 7747 6673



Rainer Hepberger Managing Director Rainer.Hepberger@HL.com +44 (0) 20 7907 4224



Daniel Fritz Managing Director Daniel.Fritz@HL.com +41 (0) 43 499 43 59



Andrew Murray-Lyon Director AMurray-Lyon@HL.com +44 (0) 20 7747 2708



Allan Burton Senior Vice President ABurton@HL.com 415.273.3703



Emily Letterio Vice President ELetterio@HL.com 212.497.4236



Casey DeLuca Associate CDeLuca@HL.com 646.259.7434

Houlihan Lokey



Houlihan Lokey is the trusted advisor to more top decisionmakers than any other independent global investment bank.

Corporate Finance

	22 M&A Advisory Rankings obal Transactions Under \$1 Billion	
	Advisor	Deals
1	Houlihan Lokey	381
2	Rothschild & Co	369
3	JP Morgan	217
4	Lazard	206
5	Goldman Sachs & Co	203
Sour	ce: Refinitiv. Excludes accounting firms and brokers.	

No. 1 Global M&A Advisor Under \$1 Billion

No. 1 U.S. M&A Advisor

Leading Capital Markets Advisor

Financial Restructuring

2022 Global Distressed Debt & Bankruptcy Restructuring Rankings		
	Advisor	Deals
1	Houlihan Lokey	58
2	PJT Partners Inc	30
3	Lazard	29
4	Rothschild & Co	25
5	Moelis & Co	21
Source: Refinitiv.		

No. 1 Global Restructuring Advisor

1,500+ Transactions Completed Valued at More Than \$3.0 Trillion Collectively


Financial and Valuation Advisory

1998 to 2022 Global M&A Fairness Advisory Rankings		
	Advisor	Deals
1	Houlihan Lokey	1,232
2	JP Morgan	1,030
3	Duff & Phelps, A Kroll Business	938
4	Morgan Stanley	725
5	BofA Securities Inc	710
Sour	ce: Refinitiv. Announced or completed transactions.	

No. 1 Global M&A Fairness Opinion Advisor Over the Past 25 Years

1,000+ Annual Valuation Engagements

Houlihan Lokey's Healthcare Group Is a Leading Advisor to Healthcare Companies



Tombstones included herein represent transactions closed from 2015 forward.

*Selected transactions were executed by Houlihan Lokey professionals while at other firms acquired by Houlihan Lokey or by professionals from a Houlihan Lokey joint venture company.

MCM Outlook: 2023 and Beyond

We are pleased to present our Medical Contract Manufacturing (MCM) industry thought piece. If there is additional content you would find useful or if you are interested in discussing any of our perspectives further, please don't hesitate to reach out. We look forward to staying in touch with you.

Houlihan Lokey's Outlook

The medical device industry has increasingly ramped up its outsourcing efforts, following suit with its predecessor, the biopharmaceutical industry, which has successfully embraced outsourcing for 30+ years. Medical technology and diagnostics companies have realized greater speed to market and increased production/ workflow efficiencies by outsourcing across multiple functional areas within production processes. Going forward, we expect companies across the medical technology landscape to outsource a portion or all of their production efforts to ultimately ease the burden on internal resources while keeping costs low. While medical technology manufacturers continue to face industry pressure, particularly related to rapid innovation and product development, the shift toward greater outsourcing efforts is a key step for many players across medtech subsectors.



Large Global MCM Market Opportunity

Key Takeaways

Given the multitude of clear industry tailwinds, we believe there is significant opportunity within MCM despite any lingering impacts of the pandemic and, more recently, global economic uncertainty.

- 1. Medical outsourcing penetration is driven by complex regulatory burdens, increased focus on technological innovation, speed to market and cost efficiencies, and capacity dynamics.
- 2. Underlying dynamics within the historically recession-resilient medical technology sector will continue to benefit the MCM industry.
- 3. M&A activity, which is predominantly led by private equity, slowed in the second half of 2022, driven by an increased cost of capital and overall macroeconomic headwinds.
- Despite a slowdown in M&A activity toward the end of 2022, the sector remains ripe for consolidation, with significant opportunity for smaller assets as sponsors seek to execute on buy-and-build strategies.

While demand has largely rebounded in the aftermath of the pandemic, industry players will continue to face some headwinds heading into 2023, including hospital staffing shortages in the face of increased procedure demand, inflationary-related pressures, and supply chain disruption. This will be an important inflection point for industry constituents, with the high-performing players using these challenging dynamics to ultimately showcase their value creation. Said differently, the top assets will differentiate themselves by providing support and services beyond superior manufacturing, including on-time delivery, supply chain management, and collaborative problem solving.

Sources: MassMEDIC, Precedence Research, Wall Street equity research, public domain.

MCM Outlook: 2023 and Beyond (cont.)

Factors Driving Outsourcing Demand



Permanent pursuit of cost savings and operational efficiency to free resources toward their core competencies.



Increasing tendency to outsource higher-value phases (product design, engineering, or complex manufacturing).



Competency gaps in certain high-growth domains of innovation traditionally outside of the OEM's capabilities.



Strong growth of end markets that already exhibit a high degree of outsourcing (Robotics, structural heart, and wearable devices).



Efficient manufacturing and quicker production to enable OEMs to capture economic benefits of new and improved products before competitors.

Competitive Trends



Heightened competition among more vertically integrated players with diversified competencies and a growing footprint.



Dual-pricing trajectory sees undifferentiated contract manufacturers suffering a decline in prices while technology-rich outsourced service providers experience stable to rising prices.



Companies compete early in the product lifecycle, striving to develop or acquire product development capabilities in a trajectory of **upstream integration** in the value chain.



Diversity of qualified suppliers is increasingly paramount as the global supply chain crisis continues to persist, resulting in extended lead times for key materials.

The pursuit of competitive advantages continues to drive consolidation in the space as key constituents seek to offer outsourcing services along the value chain.

KEY VALUATION DRIVERS

1	Multisite, Low-Cost Manufacturing Global supply chain bottlenecks and labor shortages created increased demand for players with nearshore and lower-cost manufacturing facilities.
	End-to-End Vertical Integration Vertically integrated, one-stop-shop solutions providers that partner with OEMs throughout the concept-to-cash continuum can drive premium valuations.
3	Diversified, Tenured Customer Base A loyal customer base driven by sticky applications in high-growth end markets and sole-sourcing dynamics is typically a key investment consideration among buyers.
4	Healthy Backlog and Recurring Revenue A robust backlog with visibility into future revenues, combined with a strong historical pipeline conversion rate, can ultimately enhance valuations.
5	Scalable Platform Buyers often focus heavily on future growth opportunities—both organically through capacity expansion and customer acquisition, etc., and inorganically via complementary acquisitions.

Sector Outlook

After several years of persistent headwinds (COVID-19-driven procedural delays and staffing shortages in 2020 and 2021, followed by challenging macroeconomic pressures in 2022), we expect medtech to fare favorably in 2023.


- 1. Decreasing numbers of COVID-19 patients in hospitals have allowed procedure volumes to return to more normalized levels, despite continued staffing shortages.
- 2. With pandemic-related pressures subsiding, we expect medtech companies to refocus on innovation and R&D in 2023, which has taken a backseat over the past few years.
- 3. Medtech sector fundamentals are expected to remain healthy despite a potential imminent recession, driven largely by a continued focus on innovation, favorable pricing dynamics, and easier access to healthcare in the U.S.

Recession-Resilient Medical Technology Sector


Industry Observation: Product Innovation

Over the past few years, new device approvals have declined, driven by a significant decrease in de novo PMA and 510(k) submissions. We expect OEMs to refocus on innovation in 2023, which should facilitate a strong cadence of novel product innovation going forward.

Novel Device Approvals



Contract manufacturing is mission-critical for OEMs as they seek to free resources internally to refocus innovation efforts.




The medical technology sector has historically outperformed the broader market during previous recessions, predominantly led by key large, diversified players.

Sources: S&P Capital IQ, Wall Street Equity research, FDA, public domain. Note: Large Cap Medtech names include ABT, BAX, BDX, BSX, EW, ISRG, MDT, SYK, ZBH.

Medical Contract Manufacturing Value Chain

Medical contract manufacturing services are expected to grow in volume and value across the outsourcing chain, driven by the OEMs' pursuit of new competencies that may spur competitiveness in new markets at a variable cost.



Outsourcing Potential



Outsourced design services will enhance OEMs' internal R&D capabilities in areas outside of their traditional competencies, a trend boosted by innovationrelated pressures.



Demand for outsourced tooling services will be driven by growth of injection molding volumes and the rise of sophisticated technical plastics (e.g., microfluidics).



Components manufacturing is the most mature segment of the medical contract manufacturing industry but is expected to maintain healthy growth levels as OEMs look to lighten the burden on internal resources.



VERY HIGH


OEMs are expected to continue to outsource assembly and sterilization, especially as it relates to technically complex processes and higher volume production, ultimately to boost scalability and turnaround times.



MODERATE

While the volume of outsourced packaging and labeling services will grow, packaging and labeling outsourcing will likely remain a lower priority, especially on a standalone basis.

MCM Landscape Across the Value Chain



Sources: MassMEDIC, Wall Street equity research, public domain.

Note: The industry players presented in this landscape are grouped according to key competency within the outsourcing value chain; however, they might also have complementary/ secondary capabilities in additional areas.

(1) Others include blow molding, additive manufacturing, manufacturing in electronics, polymer 3D printing, microfluidics, etc.

Select Recent Transactions

Private equity buyers continue to lead M&A activity in the medical contract manufacturing space with platform investments as well as bolt-on acquisitions. Summarized below are select recent medical contract manufacturing transactions led by financial sponsors and strategic buyers. To learn more about key buyers and valuation drivers, please contact Houlihan Lokey's Medical Technology team.

Date	Acquirer	Target	Target Description
Jan-23	Outsourcing (PPC)	J-Pac Medical Medical Device Outsourcing	Contract manufacturer for single-use medical and diagnostic devices
Jan-23	Acrotec Group (Carlyle)	AVIAL	Manufactures high-precision components for the medical industry, specializing in orthopedic implants for spine, trauma, and extremities
Jan-23	RESONETICS (Carlyle / GTCR)	Memry Corporation / SAES Smart Materials	Leading supplier with a broad set of capabilities focused on nitinol, enabling technological advances in an array of therapeutic areas
Jan-23			Manufacturer specializing in miniature, deep-drawn medical device and commercial components
Dec-22	(Jordan Company)		Contract manufacturing company specializing in precision grinding, providing surgical cutting tools and precision ground instruments to the medical industry
Nov-22	(Jordan Company)	ALPHA Mandataria R Dougs, LLC	Precision contract manufacturer specializing in highly engineered and complex surgical devices for spine, trauma, large joint, and dental applications
Nov-22	(Truarc)	GI\$balMed Inc.	Pure-play medical plastic tubing and extrusion manufacturer
Aug-22	T RUARC	Meters - Devices - Ne	Contract manufacturer specializing in injection molding, tube extrusion, blow molding, dip molding, and dip coating
Jul-22	(Jordan Company)	Med Torque	Precision manufacturer of orthopedic instruments and implants
Jun-22	iCG		Plastic injection molder for prototype and low-volume production requirements
Apr-22	🕦 Integer		Delivers development and manufacturing solutions for implantable medical devices
Mar-22	(Jordan Company)	Market Services Corporation	Manufacturer of custom-designed ultrasonic subsystems for the clinical and laboratory diagnostic markets
Feb-22	ALTARIS		Designs, develops, engineers, manufactures, and packages miniature interventional, implantable, and body-worn medical devices
Jan-22	(Graham Partners)	MEDICAL	Medical device component manufacturer specializing in injection molding, precision machining, and tooling for industry-leading medical device OEMs
Jan-22	TEAM (Clearlake)		Manufacturer of FDA Class I and II consumable medical devices, specializing in patient monitoring, wound care, and compression therapy treatments
Jan-22	ACP	Millstone	Comprehensive solutions provider of quality-critical, post-manufacturing services including supply chain and logistics management
Jan-22	OVITALPATH. (Inverness Graham)	MODERN CATHETER TECHNOLOGIES	Manufacturer of advanced catheter delivery systems, focused in the neurovascular and electrophysiology markets

MD&M West 2023: Key Takeaways

Houlihan Lokey bankers recently attended MD&M West, a design and manufacturing conference built to connect industry constituents across the outsourcing value chain. We met with various medical technology professionals, innovators, and industry leaders, which ultimately strengthened our conviction and excitement around the space. Summarized below are key takeaways following the conference.

Key Takeaways

Sponsor and Strategic Buyer Interest Remains Strong	Medical contract manufacturing assets continue to draw interest from both the strategic and sponsor communities, whose conviction in the space, and the associated secular tailwinds, remains high. Notably, we observed significant attendance from the universe of sponsors, who remain eager to find both add-on targets for existing portfolio companies and new platform opportunities of scale. During this slower period of reduced M&A activity, buyers noted the opportunity to learn about different capabilities and competencies within MCM to decide where they want to invest time and resources once deal flow normalizes.
M&A Activity Is Expected to Increase in 2H 2023	Deal volume has noticeably dwindled in recent months due to downward pressure on transaction multiples, a more skittish lender environment, and broader macroeconomic challenges, leading many sellers to enter "wait-and-see" mode. Despite this drastic slowdown following two years of strong M&A volumes, activity is expected to pick up toward the back half of the year. While the buyer environment remains eager, we suspect sellers, particularly founders, will seek partners with strong track records in the space.
Scarcity Value Will Drive Multiples for A+ Assets	Despite overall market softening toward the end of 2022 and into 2023, buyers remain willing to pay a premium for A+ assets. Given significant recent M&A volume (particularly in 2021) and the typical sponsor hold period, we expect fewer new opportunities in the market this year and a handful of assets coming back to market for a second time in 2023.
Existing Platforms Are Actively Pursuing Design and Development Assets	Over the past several years, we have observed companies seeking add-on opportunities to diversify end-market exposure, broaden geographic reach, and enhance solution offerings through complementary capabilities. While these established companies have executed on this manufacturing-focused strategy, other businesses are hungry for upstream design, development, and engineering capabilities. Acquiring assets focused on design and development will enable contract manufacturers to partner with OEMs earlier in the product lifecycle and ultimately capture additional wallet share.
Increased Demand for Nearshore Manufacturing Facilities	MCMs have expressed a desire to establish or grow nearshore manufacturing capacity, particularly in the southern portion of North America and Central America, citing customer requests as the leading motivation. Nearshore manufacturing has become increasingly important in facilitating supply chain stability, minimizing overall production and labor costs, and reducing lead times. However, this trend is not exclusive to the contract manufacturing space. As companies across industries also seek to relocate operations, the labor force may see some constraints, particularly in smaller countries like Costa Rica.

Medical Technology Team Bios



Keith Barry

Managing Director, Head of Medical Technology KBarry@HL.com | 415.273.3708

Mr. Barry is Head of Houlihan Lokey's Medical Technology practice. He has more than two decades of healthcare investment banking experience and has managed a wide variety of projects, from mergers and acquisitions to equity and debt capital raises for the broader medical technology sector, including diagnostics and life science tools. He is now based in San Francisco, with previous experience at Wells Fargo Securities, Citi, UBS, and Salomon Smith Barney in both New York and London.



Jon Guskind Managing Director JGuskind@HL.com | 212.497.7807

Mr. Guskind is a Managing Director in Houlihan Lokey's Healthcare Group. He has more than a decade of healthcare investment banking experience and has managed a wide variety of projects, from mergers and acquisitions to equity and debt capital raises for the broader medical technology, diagnostics, and life science tools sectors. Mr. Guskind is based in New York, with previous experience in both London and Chicago. Prior to joining Houlihan Lokey, Mr. Guskind held roles at Morgan Stanley and BNP Paribas.



Paul Tomasic

Managing Director, Head of European Healthcare PTomasic@HL.com | +44 (0) 20 7747 6673

Mr. Tomasic is Head of Houlihan Lokey's European Healthcare team. He has more than two decades of healthcare investment banking experience and has managed a wide variety of projects, from mergers and acquisitions to equity and debt capital raises for the broader healthcare sector, including work with medical technology, life sciences, and healthcare services companies. He is based in London, with previous experience in New York and Tokyo. Prior to joining Houlihan Lokey, Mr. Tomasic held various roles at RBC, Citi, UBS, L.E.K., and Arthur Andersen.



Rainer Hepberger

Managing Director Rainer.Hepberger@HL.com | +44 (0) 20 7907 4224

Mr. Hepberger is a Managing Director in Houlihan Lokey's Healthcare Group. He has more than 15 years of industry experience, particularly in medical technology, healthcare distribution, outsourcing, and consumer health. During his career, Mr. Hepberger has advised on more than 50 M&A transactions across Benelux, DACH, the UK, Scandinavia, Spain, and Israel. Prior to joining Houlihan Lokey, Mr. Hepberger held roles at William Blair, Raymond James, PwC, and MBT.



Daniel Fritz

Managing Director Daniel.Fritz@HL.com | +41 (0) 43 499 43 59

Mr. Fritz is a Managing Director in Houlihan Lokey's Healthcare Group. He is based in the firm's Zurich office. Previously, Mr. Fritz was a Managing Director at GCA Altium, which was acquired by Houlihan Lokey in 2021.

Disclaimer

© 2023 Houlihan Lokey. All rights reserved. This material may not be reproduced in any format by any means or redistributed without the prior written consent of Houlihan Lokey.

Houlihan Lokey is a trade name for Houlihan Lokey, Inc., and its subsidiaries and affiliates, which include the following licensed (or, in the case of Singapore, exempt) entities: in (i) the United States: Houlihan Lokey Capital, Inc., and Houlihan Lokey Advisors, LLC, each an SEC-registered broker-dealer and member of FINRA (www.finra.org) and SIPC (www.sipc.org) (investment banking services); (ii) Europe: Houlihan Lokey Advisory Limited, Houlihan Lokey EMEA, LLP, Houlihan Lokey (Corporate Finance) Limited, and Houlihan Lokey UK Limited, authorized and regulated by the U.K. Financial Conduct Authority; Houlihan Lokey (Europe) GmbH, authorized and regulated by the German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht); (iii) the United Arab Emirates, Dubai International Financial Centre (Dubai): Houlihan Lokey (MEA Financial Advisory) Limited, regulated by the Dubai Financial Services Authority for the provision of advising on financial products, arranging deals in investments, and arranging credit and advising on credit to professional clients only; (iv) Singapore: Houlihan Lokey (Singapore) Private Limited and Houlihan Lokey Advisers Singapore Private Limited, each an "exempt corporate finance adviser" able to provide exempt corporate finance advisory services to accredited investors only; (v) Hong Kong SAR: Houlihan Lokey (China) Limited, licensed in Hong Kong by the Securities and Futures Commission to conduct Type 1, 4, and 6 regulated activities to professional investors only; (vi) India: Houlihan Lokey Advisory (India) Private Limited, registered as an investment adviser with the Securities and Exchange Board of India (registration number INA000001217); and (vii) Australia: Houlihan Lokey (Australia) Pty Limited (ABN 74 601 825 227), a company incorporated in Australia and licensed by the Australian Securities and Investments Commission (AFSL number 474953) in respect of financial services provided to wholesale clients only. In the United Kingdom, European Economic Area (EEA), Dubai, Singapore, Hong Kong, India, and Australia, this communication is directed to intended recipients, including actual or potential professional clients (UK, EEA, and Dubai), accredited investors (Singapore), professional investors (Hong Kong), and wholesale clients (Australia), respectively. Other persons, such as retail clients, are NOT the intended recipients of our communications or services and should not act upon this communication.

Houlihan Lokey gathers its data from sources it considers reliable; however, it does not guarantee the accuracy or completeness of the information provided within this presentation. The material presented reflects information known to the authors at the time this presentation was written, and this information is subject to change. Any forward-looking information and statements contained herein are subject to various risks and uncertainties, many of which are difficult to predict, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. In addition, past performance should not be taken as an indication or guarantee of future performance and information contained herein may be subject to variation as a result of currency fluctuations. Houlihan Lokey makes no representations or warranties, expressed or implied, regarding the accuracy of this material. The views expressed in this material accurately reflect the personal views of the authors regarding the subject securities and issuers and do not necessarily coincide with those of Houlihan Lokey. Officers, directors, and partners in the Houlihan Lokey group of companies may have positions in the securities of the companies discussed. This presentation does not constitute advice or a recommendation, offer, or solicitation with respect to the securities of any company discussed herein, is not intended to provide information upon which to base an investment decision, and should not be construed as such. Houlihan Lokey or its affiliates may from time to time provide investment banking or related services to these companies. Like all Houlihan Lokey employees, the authors of this presentation receive compensation that is affected by overall firm profitability.



Corporate Finance Financial Restructuring Financial and Valuation Advisory

HL.com

Houlihan Lokey